» Articles » PMID: 23966223

The Systemic Inflammatory Response and Its Relationship to Pain and Other Symptoms in Advanced Cancer

Overview
Journal Oncologist
Specialty Oncology
Date 2013 Aug 23
PMID 23966223
Citations 56
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Inflammation has been identified as a hallmark of cancer and may be necessary for tumorgenesis and maintenance of the cancer state. Inflammation-related symptoms are common in those with cancer; however, little is known about the relationship between symptoms and systemic inflammation in cancer. The aim of the present study was to examine the relationship between symptoms and systemic inflammation in a large cohort of patients with advanced cancer.

Methods: Data from an international cohort of patients with advanced cancer were analyzed. Symptoms and patient-related outcomes were recorded using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire--Core Questionnaire. Systemic inflammation was assessed using C-reactive protein levels. The relationship between these symptoms and systemic inflammation was examined using Spearman rank correlation (ρ) and the Mann-Whitney U test.

Results: Data were available for 1,466 patients across eight European countries; 1,215 patients (83%) had metastatic disease at study entry. The median survival was 3.8 months (interquartile range [IQR] 1.3-12.2 months). The following were associated with increased levels of inflammation: performance status (ρ = .179), survival (ρ = .347), pain (ρ = .154), anorexia (ρ = .206), cognitive dysfunction (ρ = .137), dyspnea (p= .150), fatigue (ρ = .197), physical dysfunction (ρ = .207), role dysfunction (ρ = .176), social dysfunction (ρ = .132), and poor quality of life (ρ = .178). All were statistically significant at p < .001.

Conclusion: The results show that the majority of cancer symptoms are associated with inflammation. The strength of the potential relationship between systemic inflammation and common cancer symptoms should be examined further within the context of an anti-inflammatory intervention trial.

Citing Articles

Anamorelin Efficacy in Non-Small-Cell Lung Cancer Patients With Cachexia: Insights From ROMANA 1 and ROMANA 2.

Laird B, Skipworth R, Bonomi P, Fallon M, Kaasa S, Giorgino R J Cachexia Sarcopenia Muscle. 2025; 16(1):e13732.

PMID: 39992021 PMC: 11848863. DOI: 10.1002/jcsm.13732.


Hypnosis Sedation Used in Breast Oncologic Surgery Significantly Decreases Perioperative Inflammatory Reaction.

Berliere M, Roelants F, Duhoux F, Gerday A, Piette N, Lacroix C Cancers (Basel). 2025; 17(1.

PMID: 39796678 PMC: 11718863. DOI: 10.3390/cancers17010049.


Association of Systemic Inflammation with Dietary Intake, Nutrition Impact Symptoms, and Eating-Related Distress Among Patients with Advanced Cancer.

Amano K, Koshimoto S, Okamura S, Sakaguchi T, Arakawa S, Matsuda Y Healthcare (Basel). 2025; 12(24.

PMID: 39765960 PMC: 11675562. DOI: 10.3390/healthcare12242533.


The Role of Wheatgrass in Colorectal Cancer: A Review of the Current Evidence.

Tamraz M, Al Ghossaini N, Temraz S Int J Mol Sci. 2024; 25(10).

PMID: 38791211 PMC: 11121291. DOI: 10.3390/ijms25105166.


Harnessing the Systemic Biology of Functional Decline and Cachexia to Inform more Holistic Therapies for Incurable Cancers.

Willbanks A, Seals M, Karmali R, Roy I Cancers (Basel). 2024; 16(2).

PMID: 38254849 PMC: 10814065. DOI: 10.3390/cancers16020360.


References
1.
Lee B, Dantzer R, Langley K, Bennett G, Dougherty P, Dunn A . A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation. 2004; 11(5):279-92. DOI: 10.1159/000079408. View

2.
Fearon K, Strasser F, Anker S, Bosaeus I, Bruera E, Fainsinger R . Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011; 12(5):489-95. DOI: 10.1016/S1470-2045(10)70218-7. View

3.
Neumann S, Doubell T, Leslie T, Woolf C . Inflammatory pain hypersensitivity mediated by phenotypic switch in myelinated primary sensory neurons. Nature. 1996; 384(6607):360-4. DOI: 10.1038/384360a0. View

4.
Ma C, Bandukwala S, Burman D, Bryson J, Seccareccia D, Banerjee S . Interconversion of three measures of performance status: an empirical analysis. Eur J Cancer. 2010; 46(18):3175-83. DOI: 10.1016/j.ejca.2010.06.126. View

5.
Aaronson N, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez N . The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85(5):365-76. DOI: 10.1093/jnci/85.5.365. View